The risks of pityriasis rosea in pregnancy: a review. [PDF]
Int J Womens DermatolObjective: This review aims to consolidate available evidence, identify research gaps, and advocate for a more informed approach to the management of pityriasis rosea in pregnant individuals.
Manduca S +5 more
europepmc +2 more sources
Dermoscopic features of pityriasis rosea. [PDF]
BMJ Case Rep, 2023 © BMJ Publishing Group Limited 2023. No commercial reuse. See rights and permissions. Published by BMJ. DESCRIPTION A woman in her 20s presented with an erythematous, itchy, scaly rash on her trunk and extremities for 3 weeks duration.
Vasisht S, Kansal NK.
europepmc +2 more sources
Line-field confocal optical coherence tomography assessment of pityriasis rosea. [PDF]
JAAD Case Rep, 2023 LC-OCT: line-field confocal optical coherence tomography PR: pityriasis rosea CLINICAL PRESENTATION A healthy 24-year-old man presented with a discrete erythematous scaly plaque on the right mid-back associated with pruritus for 4 weeks.
Pathak GN, Truong TM, Rao BK.
europepmc +2 more sources
Comparative Efficacy of Different Pharmacological Treatments for Pityriasis Rosea: A Network Meta-Analysis. [PDF]
J Clin MedBackground/Objectives: Pityriasis rosea (PR) is a self-limiting exanthematous disease associated with the endogenous reactivation of human herpesviruses (HHV)-6 and HHV-7. Classically, the lesions gradually resolve, leaving no sequelae.
Ciccarese G +6 more
europepmc +2 more sources
A Review of Pityriasis Rosea in Relation to SARS-CoV-2/COVID-19 Infection and Vaccination. [PDF]
Cureus, 2023 Pityriasis rosea (PR) is an acute exanthematous disease, commonly preceded by a primary solitary herald patch followed by the onset of smaller scaly papulosquamous lesions within days to weeks.
Wong N +4 more
europepmc +2 more sources
Domperidone‐induced pityriasis rosea‐like drug eruption [PDF]
Clinical Case Reports, 2022 Pityriasis rosea is a common, acute, self limiting inflammatory skin disease. Pityriasis rosea‐like eruptions (PR‐LE) have been reported after drugs. The clinical presentation of PR‐LE can be distinguished from pityriasis rosea.
Sarra Saad +3 more
doaj +2 more sources
Pityriasis Rosea Induced by COVID-19 Vaccination
European Journal of Case Reports in Internal Medicine, 2022 It is increasingly recognized that SARS-CoV-2 infection and COVID-19 vaccines have been associated with skin disorders, including pityriasis rosea. It has been reported that pityriasis rosea has been triggered by several vaccines, as a rare side-effect ...
Elina Khattab +2 more
doaj +2 more sources
Atypical Rash as a Presentation of Pityriasis Rosea in a 23-Month-Old. [PDF]
CureusPityriasis rosea is a self-limiting skin disorder that can occur in pediatric patients. We report an atypical presentation of a 23-month-old male with a generalized rash similar in appearance to pityriasis rosea.
Tilak K, Ray E, Joseph M.
europepmc +2 more sources
Pityriasis Rosea-Like Eruption following anti-fatigue traditional herbs: Aconitum carmichaelii Debx and Panax Ginseng suspected. [PDF]
BMC Complement Med TherTraditional herbs have a history of clinical use in anti-fatigue. However, several adverse effects of herbs have been identified. Pityriasis rosea-like eruption (PR-LE) is a rare cutaneous complication of herbs.
Zeng X +7 more
europepmc +2 more sources
Pityriasis rosea, pityriasis rosea-like eruptions, and herpes zoster in the setting of COVID-19 and COVID-19 vaccination. [PDF]
Clin Dermatol, 2022 Pityriasis rosea (PR), PR–like eruptions (PR-LE), and herpes zoster have been frequently reported during the COVID-19 pandemic and following COVID-19 vaccination.
Drago F, Broccolo F, Ciccarese G.
europepmc +2 more sources